Aardvark Therapeutics, Inc.
AARD
$8.69
-$0.66-7.06%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | |||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | ||
| Total Other Revenue | -- | -- | -- | ||
| Total Revenue | -- | -- | -- | ||
| Cost of Revenue | -- | -- | -- | ||
| Gross Profit | -- | -- | -- | ||
| SG&A Expenses | 35.89% | 102.70% | 102.70% | ||
| Depreciation & Amortization | -- | -- | -- | ||
| Other Operating Expenses | -- | -- | -- | ||
| Total Operating Expenses | 196.16% | 138.06% | 138.06% | ||
| Operating Income | -196.16% | -138.06% | -138.06% | ||
| Income Before Tax | -98.29% | -149.41% | -149.41% | ||
| Income Tax Expenses | -- | -- | -- | ||
| Earnings from Continuing Operations | -98.29% | -149.41% | -149.41% | ||
| Earnings from Discontinued Operations | -- | -- | -- | ||
| Extraordinary Item & Accounting Change | -- | -- | -- | ||
| Minority Interest in Earnings | -- | -- | -- | ||
| Net Income | -98.29% | -149.41% | -149.41% | ||
| EBIT | -196.16% | -138.06% | -138.06% | ||
| EBITDA | -- | -- | -- | ||
| EPS Basic | -97.09% | -148.80% | -148.80% | ||
| Normalized Basic EPS | -156.73% | -228.22% | -228.22% | ||
| EPS Diluted | -97.09% | -148.80% | -148.80% | ||
| Normalized Diluted EPS | -156.73% | -228.22% | -228.22% | ||
| Average Basic Shares Outstanding | 0.61% | 0.25% | 0.25% | ||
| Average Diluted Shares Outstanding | 0.61% | 0.25% | 0.25% | ||
| Dividend Per Share | -- | -- | -- | ||
| Payout Ratio | -- | -- | -- | ||
